Characteristics of study population
| Variables | without COPD (n=65) | With COPD (n=65) | p Value |
|---|---|---|---|
| Age (years), mean±SD | 70±11 | 71±10 | 0.4 |
| Cardiovascular risk factors, n. (%) | |||
| Men | 52 (80) | 50 (77) | 0.9 |
| Diabetes mellitus | 14 (21) | 14 (21) | 0.9 |
| Hypertension | 53 (81) | 55 (84) | 0.3 |
| Current smoker | 14 (21) | 12 (18) | 0.5 |
| Hypercholesterolemia | 31 (47) | 30 (46) | 0.7 |
| Prior medical history, n. (%) | |||
| Renal failure | 3 (4) | 3 (4) | 0.6 |
| MI | 24 (36) | 21 (32) | 0.7 |
| PCI | 23 (38) | 21 (36) | 0.6 |
| CABG | 2 (3) | 3 (4) | 0.8 |
| Clinical presentation, n (%) | |||
| ST-segment elevation MI | 11 (17) | 11 (17) | 0.9 |
| No ST-segment elevation ACS | 35 (54) | 36 (55) | 0.7 |
| Stable angina | 17 (26) | 18 (27) | 0.7 |
| Laboratory data, mean±SD | |||
| Platelet count (u×103/mm3) | 230±65 | 239±70 | 0.3 |
| White blood cells (u/mm3) | 8.2±2 | 8.5±2 | 0.5 |
| Haematocrit (%) | 42±6 | 43±5 | 0.5 |
| Cardiac medical therapy, n (%) | |||
| ACE inhibitors | 60 (92) | 60 (92) | 0.9 |
| Β-blockers | 53 (81) | 49 (75) | 0.1 |
| Statins | 61 (93) | 60 (92) | 0.9 |
| Clinical outcome at 2 years, n (%) | |||
| Death | 9 (13) | 10 (15) | 0.2 |
| MI | 3 (5) | 5 (7) | 0.3 |
| Heart failure | 9 (13) | 11 (18) | 0.4 |
| Gene polymorphisms, n. (%) | |||
| CYP2C19 *2 carriers | 14 (21) | 12 (18) | 0.4 |
| CYP219 *17 carriers | 25 (38) | 24 (37) | 0.8 |
| ABCB1 CC homozygotes | 16 (24) | 14 (21) | 0.5 |
| PON1 192 RR homozygotes | 5 (8) | 6 (9) | 0.8 |
| P2Y12 VerifyNow (PRU), mean±SD | |||
| Baseline | 182±100 | 226±105 | 0.01 |
| 1 month | 148±79 | 184±77 | 0.009 |
| Multiplate Analyzer (AU×min), median (IQR) | |||
| Baseline TRAP test | 953 (605–1104) | 1119 (867–1388) | 0.002 |
| ASPI test | 235 (139–352) | 349 (192–645) | 0.02 |
| ADP test | 504 (337–800) | 679 (438–934) | 0.03 |
| ADP HS test | 317 (224–535) | 514 (287–737) | 0.01 |
| 1 month TRAP test | 796 (589–908) | 1054 (763–1123) | <0.001 |
| ASPI test | 137 (37–242) | 352 (232–427) | <0.001 |
| ADP test | 309 (277–543) | 677 (324–891) | <0.001 |
| ADP HS test | 212 (205–342) | 567 (219–752) | <0.001 |
Multiplate analyzer result is expressed in area under the curve of arbitrary units (AU×min). P2Y12 VerifyNow, ADP test and ADP HS test evaluate the platelet pathway normally inhibited by clopidogrel. ASPI test evaluates the platelet pathway normally inhibited by aspirin. TRAP test evaluates the general platelet function after stimulus with thrombin.
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; HS, high sensitivity; MI, myocardial infarction; PCI, percutaneous coronary intervention; PON, paraoxonase; PR, platelet reactivity; PRU, P2Y12 reactivity unit; TRAP, thrombin receptor activating peptide.